Literature DB >> 64915

Antithrombin-heparin cofactor.

P S Damus, R D Rosenberg.   

Abstract

Mesh:

Substances:

Year:  1976        PMID: 64915     DOI: 10.1016/s0076-6879(76)45056-5

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


× No keyword cloud information.
  9 in total

1.  Contribution of blood and systemic circulation to the processing of pro-(atrial natriuretic factor).

Authors:  K K Murthy; G Thibault; M Cantin
Journal:  Biochem J       Date:  1988-03-15       Impact factor: 3.857

2.  Abnormal antithrombin III with defective serine protease binding (antithrombin III "Denver").

Authors:  J E Sambrano; L J Jacobson; E B Reeve; M J Manco-Johnson; W E Hathaway
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

Review 3.  Effect of heparin and heparin fractions on platelet aggregation.

Authors:  E W Salzman; R D Rosenberg; M H Smith; J N Lindon; L Favreau
Journal:  J Clin Invest       Date:  1980-01       Impact factor: 14.808

4.  Thrombin causes increased monocytic-cell adhesion to endothelial cells through a protein kinase C-dependent pathway.

Authors:  P E DiCorleto; C A de la Motte
Journal:  Biochem J       Date:  1989-11-15       Impact factor: 3.857

5.  Evidence of normal functional levels of activated protein C inhibitor in combined Factor V/VIII deficiency disease.

Authors:  W M Canfield; W Kisiel
Journal:  J Clin Invest       Date:  1982-12       Impact factor: 14.808

6.  Evaluation of critical groups required for the binding of heparin to antithrombin.

Authors:  D H Atha; A W Stephens; R D Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

7.  Detection of protein C activation in humans.

Authors:  K A Bauer; B L Kass; D L Beeler; R D Rosenberg
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

8.  Elevated factor Xa activity in the blood of asymptomatic patients with congenital antithrombin deficiency.

Authors:  K A Bauer; T L Goodman; B L Kass; R D Rosenberg
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

9.  Circulating heparan sulfate proteoglycan anticoagulant from a patient with a plasma cell disorder.

Authors:  M S Khoory; M E Nesheim; E J Bowie; K G Mann
Journal:  J Clin Invest       Date:  1980-03       Impact factor: 14.808

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.